DENVER, Colo. (247marketnews.com) — Agenus (NASDAQ:AGEN) has taken a significant step toward advancing one of its highest-priority oncology programs, announcing an oversubscribed private placement worth up to $340 million to support the planned Phase 3 ROBBIN trial of its investigational immunotherapy combination, botensilimab (BOT) plus balstilimab (BAL), in microsatellite-stable (MSS) colon cancer. The financing includes $85 million in upfront proceeds, with the potential for an additional $255 million if investors exercise accompanying warrants. According to the company, full funding could support operations through the end of 2031 while carrying the program through multiple key clinical milestones.
The financing arrives as Agenus sharpens its strategic focus on the neoadjuvant treatment setting, where patients receive therapy before surgery. MSS colon cancer represents approximately 85% of colorectal cancer cases, yet immunotherapy has historically shown limited effectiveness in this population. Agenus believes BOT+BAL may help overcome that challenge by stimulating both innate and adaptive immune responses, positioning the combination for a disease area where no new curative-intent therapies have been approved in more than two decades.
That strategy is supported by encouraging early clinical findings. Across the company’s Phase 2 NEST and UNICORN studies, BOT+BAL produced pathologic responses in approximately 60–70% of treated patients, major pathologic responses in roughly 35–40%, and pathologic complete responses in approximately 30% of patients. While these results come from earlier-stage trials and require confirmation in larger randomized studies, they helped establish the rationale for launching the registrational ROBBIN trial.
The planned global Phase 3 study is expected to enroll 850 patients with high-risk Stage II and Stage III MSS colon cancer and compare neoadjuvant BOT+BAL followed by standard treatment against standard treatment alone. The primary endpoint will be event-free survival, with interim pathologic response data anticipated in the second half of 2027, an interim event-free survival analysis expected in 2029, and a final analysis projected for 2030.
To concentrate resources on this potentially larger opportunity, Agenus also announced it will discontinue financial support for the ongoing BATTMAN Phase 3 trial in late-line metastatic MSS colorectal cancer while continuing to meet obligations for patients currently receiving treatment. The decision reflects the company’s effort to prioritize capital toward a program it believes offers the greatest long-term potential.
Although significant clinical, regulatory, and commercialization risks remain, as is typical for late-stage biotechnology development, the combination of fresh institutional financing, alignment with the FDA on key aspects of the Phase 3 design, and encouraging earlier clinical data marks an important milestone for Agenus. The ROBBIN trial now becomes the company’s central value driver, with several major clinical catalysts scheduled over the next four years.
Sources
-
Business Wire – Agenus Announces Oversubscribed Private Placement:
https://www.businesswire.com/news/home/20260713089967/en/ -
Agenus Investor Relations:
https://investor.agenusbio.com -
Agenus Corporate Website:
https://www.agenusbio.com -
ClinicalTrials.gov (Agenus Clinical Programs):
https://clinicaltrials.gov -
American Cancer Society – Colorectal Cancer Statistics:
https://www.cancer.org/cancer/types/colon-rectal-cancer.html
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.